SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as the community discusses the implications of the company's recent Phase III trial failure for its Alzheimer's drug, with some investors expressing disappointment while others see it as an opportunity to buy. Despite the setback, there is optimism surrounding Novo Nordisk's position in the weight loss market, particularly with the potential upcoming approval of its oral Wegovy pill and comparison of CagriSema vs Zepbound study results.

Pony.ai, Inc. develops artificial intelligence-based robot designed for autonomous driving. The firm's software algorithms and infrastructure enables a vehicle to perceive its surroundings, predict what others will do, and maneuver itself accordingly. The company was founded by Jun Peng and Tian Cheng Lou in November 4, 2016 and is headquartered in Guangzhou, China.

Pony AI Inc. - ADR

Pony AI Inc

Pony AI is trending due to news of expanded robotaxi operations and partnerships, including a recent permit in Shanghai. The community is weighing the company's growth prospects against its financial performance, especially regarding profitability targets. Broader discussions involve comparing Pony AI to competitors in the autonomous driving space and assessing the impact of these developments on its market position.

Diginex Ltd. (Hong Kong) is a blockchain financial services and technology company. Its products include diginexESG, diginexLUMEN, diginexAPPRISE, diginexLUMEN Pro, and CSRD framework. The company was founded by Miles Christian Pelham on May 15, 2020 and is headquartered in London, the United Kingdom.

Diginex Ltd.

DGNX is trending due to its recent acquisition of The Remedy Project, sparking discussions about the company's expansion into human-rights remediation. The community is also actively analyzing potential trading strategies based on historical patterns of similar stocks. Options traders are closely monitoring put contracts, anticipating potential downside amidst the volatility.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is trending due to strong Q3 2025 earnings, highlighted by a 144.3% YoY revenue increase and significant growth in robotaxi revenue, with community members noting global expansion and regulatory milestones in the UAE and Switzerland. Investors are focused on WeRide's progress toward deploying hundreds of thousands of robotaxis by 2030 and its partnerships with companies like Bosch, Uber, and Grab. The conversation also includes comparisons to competitor Pony.ai, whose stock performance and institutional ownership are being weighed against WeRide's recent gains and expansion efforts.

Monad

Monad is trending as users discuss its upcoming launch and token distribution, particularly excitement around receiving tokens from the Coinbase presale. The community is actively speculating on potential price movements and strategies, with some comparing it to other recent launches. There's also discussion around the mainnet launch date.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending amid mixed sentiment, as discussions range from its ties to controversial figures to its evolving stance on cryptocurrency and potential competition with Bitcoin. The community is actively debating JPMorgan's investment strategies, alleged market manipulation, and the implications of its exploration of blockchain technology and stablecoins. Additionally, some traders are monitoring technical indicators to predict JPM's short-term price movements, while others are discussing potential investigations and regulatory scrutiny.

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

Alvotech ($ALVO) is trending following the announcement of European approval for AVT03, a biosimilar to Prolia and Xgeva, used in bone disease treatment, sparking bullish sentiment. Despite some community concerns about cash flow and previous manufacturing setbacks, the biosimilar's approval and analyst upgrades are fueling optimism. Discussions center on the company's potential in the biosimilar market and strategic partnerships.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending as the stock price rises following news of its AI integration with Open AI, which is expected to enhance merchant and customer experiences, with some analysts predicting a significant price target increase. However, some community members are skeptical about the sustainability of Shopify's growth, citing competition and valuation concerns, while others point to the company's strong position in the e-commerce sector and potential for further gains.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi-Aventis ($SNY) is trending amid speculation surrounding potential acquisitions, particularly in the MASH and obesity spaces, with $ALT, $GUTS, and $IVA being mentioned as possible targets. Community discussions revolve around the company's pipeline expansion needs and potential partnerships, with some users highlighting data integrity concerns around one of the speculated targets. The broader context involves Sanofi's strategic moves to strengthen its immunology and vaccine portfolio.

mF International Ltd. is a holding company, which engages in the development and provision of financial trading solutions through its subsidiary. It offers real-time mission critical forex, bullion and commodities trading platform solutions, financial value-added services, mobile applications, and financial information for brokers and institutional clients via internet or platform as software as a service. The company was founded by Tai Wai Lam and Chi Weng Tam on June 15, 2022, and is headquartered in Hong Kong.

mF International Ltd - Ordinary Shares - Class A

mF International Ltd

MFI is trending due to its recent $500M private placement aimed at building a Bitcoin Cash treasury, fueling speculation about a potential pivot into crypto equity. Community members are discussing the involvement of a Chinese billionaire and the possibility of MFI becoming a major player in the crypto space. The stock's volatile price action and small float are contributing to the heightened interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award

Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award...

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston PR Newswire NEW YORK, Oct. 16, 2025 NEW YORK, Oct. 16, 2025...

Retail chatter around Klotho Neurosciences picked up late Thursday after the company said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202.The designation is reserved for treatments targeting rare diseases and comes with several incentives to support development.&nbsp;These include seven years of market exclusivity, tax credits for clinical trials, and a waiver of the generic drug user fee amendments (GDUFA) user fee, independent of existing intellectual property rights.At the close on Thursday, shares of&nbsp;<a href="https://stocktwits.com/symbol/KLTO">Klotho Neurosciences</a> rose 6.6% to $1.46, before slipping 6.9% to $1.36 in after-hours trading.Last month, the company reported efforts to move forward with manufacturing and process development in preparation for clinical trials of KLTO-202.&nbsp;Klotho holds rights to a unique RNA splice variant of the human alpha‑Klotho gene, licensed from the Autonomous University of Barcelona.&nbsp;This variant produces the secreted form of Klotho protein (s‑KL), known for its neuroprotective properties in the brain and spinal cord.Animal studies conducted in mouse and non-human primate models of accelerated aging, Alzheimer's disease, and ALS have demonstrated that boosting s‑KL through gene therapy yields therapeutic benefits across all tested models, according to peer-reviewed journals.&nbsp;These findings support KLTO-202’s progression into clinical development.The company expects that process development and manufacturing will take about eight months, followed by four to six months of FDA meetings, mandated animal safety studies, an investigational new drug (IND) filing, and site preparations.&nbsp;A single-dose Phase I/II trial in ALS patients is planned for the third quarter of next year.&nbsp;In a statement, CEO Joseph Sinkule said that the therapy’s goal is to deliver therapeutic s‑KL concentrations to blood, brain, and muscle tissue.KLTO-202, which uses a muscle-specific desmin promoter to drive s‑KL expression at the neuromuscular junction, remains unapproved for human use.On Stocktwits, retail sentiment for Kloto was ‘bullish’ amid ‘high’ message volume.Kloto’s stock has more than doubled in value so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/china-s-byd-chery-accused-of-subsidy-misuse-as-ev-audit-flags-121-m-in-claims/ch8c5XCR5mQ">China’s BYD, Chery Accused Of Subsidy Misuse As EV Audit Flags $121M In Claims</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kloto Neurosciences (KLTO) said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202. (Photo credit: Getty Images)

Klotho Neurosciences Stock Jumps As FDA Grants Orphan Drug Tag To ALS Gene Therapy

The FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical trials, and a waiver of the user fee for its ALS gene therapy.

Equity

Klotho Neurosciences (KLTO) shares exploded over 780% on Monday, their biggest single-day gain on record, after the company announced breakthrough preclinical results tied to its anti-aging gene therapy.The Omaha, Nebraska-based biotech said boosting levels of a naturally occurring protein called s-KL (secreted Klotho) extended lifespan in mice by 20% and reduced signs of aging across multiple organ systems.&nbsp;The gene therapy, delivered via the AAV9 vector, showed positive effects in both standard and accelerated aging models."The results disclosed in the paper show the potential of elevating s-KL protein expression, resulting in the reduction of age-associated degeneration in multiple organs, increasing both life and health span," said CEO Joseph Sinkule.&nbsp;Klotho owns exclusive global rights to the patented therapy, based on pioneering work from researchers at Universitat Autònoma de Barcelona. The company said its patent coverage spans the U.S., Europe, and China.Earlier studies had shown that mice with increased Klotho expression could live up to 40% longer.Retail Traders Go WildThe update triggered a retail frenzy on Stocktwits as 24-hour message volume about KLTO jumped by 250,400% — the biggest surge in the healthcare sector — while the follower count spiked by over 134%.Sentiment score peaked at ‘extremely bullish’ levels (100/100) by the end of Monday.<figure class="image"><img style="aspect-ratio:1318/914;" src="https://news.stocktwits-cdn.com/KLTO_sentiment_and_message_volume_as_of_Jun_9_png_d3adf0d02d.webp" alt="KLTO sentiment and message volume as of Jun 9.png" width="1318" height="914"><figcaption>KLTO sentiment and message volume as of Jun 9. | source: Stocktwits</figcaption></figure>One user predicted the stock would surge nearly fivefold to $5.<stembedurl>https://stocktwits.com/Kcricket33/message/617354438</stembedurl>"Pretty wild news, obviously digested well today… will watch for continuation tomorrow using the pivot of today's highs in confluence with trend support as entry criteria. Range to $2.8, $3+," said another.<stembedurl>https://stocktwits.com/KevMomentum/message/617353716</stembedurl>Klotho is targeting neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, leveraging s-KL in both DNA/RNA therapies and genomics-based diagnostics.<a href="https://stocktwits.com/symbol/KLTO">KLTO stock</a> is now up over 271% YTD, returning to levels last seen in July 2024.&nbsp;However, short interest has also climbed, rising from 1.1% in January to 7.1% last week, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Klotho Neurosciences Stock Skyrockets On Anti-Aging Gene Therapy Breakthrough: Retail Traders Over The Moon

The gene therapy, delivered via the AAV9 vector, showed positive effects in both standard and accelerated aging models.

Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. It offers cell and gene therapy. The company was founded by Joseph Sinkule on August 2, 2004 and is headquartered in Omaha, NE.

KLTO
Klotho Neurosciences Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest KLTO News

KLTOKlotho Neurosciences Inc.